147 Results

People

  1. Horwitz
    Horwitz
  2. Salles
    Salles
  3. Usmani
    Usmani
  4. Zelenetz
    Zelenetz
  5. Kumar
    Kumar
  6. Perales
    Perales
  7. Batlevi
    Batlevi
  8. Moskowitz
    Moskowitz
  9. Palomba
    Palomba
  10. Shah
    Shah

Groups

  1. Department of Medicine (118)
  2. Hematologic Malignancies, Division of (74)
  3. Solid Tumor Oncology Division (61)
  4. Center for Hematologic Malignancies (53)
  5. Epidemiology and Biostatistics (26)
  6. Lymphoma (25)
  7. Weinberg Fellows (25)
  8. Biostatistics Service (23)
  9. Population Sciences Research Program (21)
  10. Survivorship Research (21)
  1. "overall response rate"
Formats
  1. Journal Article (114)
  2. Editorial (10)
  3. Review (8)
  4. Correspondence (6)
  5. Research Letter (6)
  6. Meeting Abstract (2)
  7. Guidelines (1)
Groups
  1. Department of Medicine (118)
  2. Hematologic Malignancies, Division of (74)
  3. Solid Tumor Oncology Division (61)
  4. Center for Hematologic Malignancies (53)
  5. Epidemiology and Biostatistics (26)
  6. Lymphoma (25)

More Groups

People
  1. Andrew Zelenetz (9)
  2. Gilles Salles (9)
  3. Saad Usmani (9)
  4. Steven Horwitz (9)
  5. Anita Kumar (8)
  6. Miguel-Angel Perales (8)

More People

Years
  1. 2025 (23)
  2. 2024 (41)
  3. 2023 (32)
  4. 2022 (27)
  5. 2021 (17)
  6. 2020 (6)

More Years

Publications
  1. Leukemia and Lymphoma (13)
  2. Blood (10)
  3. Haematologica (9)
  4. ESMO Open (7)
  5. Leukemia (7)
  6. Annals of Oncology (6)

More Publications

Publishers
  1. Elsevier Inc. (25)
  2. Nature Publishing Group (19)
  3. American Society of Hematology (16)
  4. Taylor & Francis Group (13)
  5. Oxford University Press (11)
  6. Ferrata Storti Foundation (9)

More Publishers

Results (147)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Pembrolizumab alone and pembrolizumab plus chemotherapy in previously treated, extrapulmonary poorly differentiated neuroendocrine carcinomas
    Journal Article

    Raj, N.; Chan, J. A.; Wang, S. J.; Aggarwal, R. R.; Calabrese, S.; DeMore, A.; Fong, L.; Grabowsky, J.; Hope, T. A.; Kolli, K. P.; more...
    British Journal of Cancer (2023)

    Fulltext@MSK | Save
  • Long-term outcomes and molecular correlates of sotorasib efficacy in patients with pretreated KRAS G12C-mutated non-small-cell lung cancer: 2-Year analysis of CodeBreaK 100
    Journal Article

    Dy, G. K.; Govindan, R.; Velcheti, V.; Falchook, G. S.; Italiano, A.; Wolf, J.; Sacher, A. G.; Takahashi, T.; Ramalingam, S. S.; Dooms, C.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Driving CARs to new places: Locally produced BCMA CAR T cells to treat multiple myeloma
    Editorial

    Sjöstrand, M.; Sadelain, M.
    Haematologica (2023)

    Fulltext@MSK | Save
  • Targeting RARA overexpression with tamibarotene, a potent and selective RARα agonist, is a novel approach in AML
    Journal Article

    de Botton, S.; Cluzeau, T.; Vigil, C.; Cook, R. J.; Rousselot, P.; Rizzieri, D. A.; Liesveld, J. L.; Fenaux, P.; Braun, T.; Banos, A.; more...
    Blood Advances (2023)

    Fulltext@MSK | Save
  • Dual targeting of CD19 and CD22 with bicistronic CAR-T cells in patients with relapsed/refractory large B-cell lymphoma
    Journal Article

    Roddie, C.; Lekakis, L. J.; Marzolini, M. A. V.; Ramakrishnan, A.; Zhang, Y.; Hu, Y.; Peddareddigari, V. G. R.; Khokhar, N.; Chen, R.; Basilico, S.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Comparative efficacy of teclistamab versus physician's choice of therapy in the long-term follow-up of APOLLO, POLLUX, CASTOR, and EQUULEUS clinical trials in patients with triple-class exposed relapsed or refractory multiple myeloma
    Journal Article

    Mateos, M. V.; Chari, A.; Usmani, S. Z.; Goldschmidt, H.; Weisel, K.; Qi, K.; Londhe, A.; Nair, S.; Lin, X.; Pei, L.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Molecularly targeted epigenetic therapy with mocetinostat in relapsed and refractory non-Hodgkin lymphoma with CREBBP or EP300 mutations: An open label phase II study
    Research Letter

    Qualls, D.; Noy, A.; Straus, D.; Matasar, M.; Moskowitz, C.; Seshan, V.; Dogan, A.; Salles, G.; Younes, A.; Zelenetz, A. D.; more...
    Leukemia and Lymphoma (2023)

    Fulltext@MSK | Save
  • Pembrolizumab in Asian patients with microsatellite-instability-high/mismatch-repair-deficient colorectal cancer
    Journal Article

    Yoshino, T.; Andre, T.; Kim, T. W.; Yong, W. P.; Shiu, K. K.; Jensen, B. V.; Jensen, L. H.; Punt, C. J. A.; Smith, D.; Garcia-Carbonero, R.; more...
    Cancer Science (2023)

    Fulltext@MSK | Save
  • Clinical outcomes associated with pembrolizumab monotherapy among adults with diffuse malignant peritoneal mesothelioma
    Journal Article

    Marmarelis, M. E.; Wang, X.; Roshkovan, L.; Grady, C. B.; Miura, J. T.; Ginsberg, M. S.; Ciunci, C. A.; Egger, J.; Walker, S.; Cercek, A.; more...
    JAMA Network Open (2023)

    Fulltext@MSK | Save
  • Improving systemic therapy for fumarate hydratase–deficient renal cell carcinoma
    Correspondence

    Carlo, M. I.
    European Urology (2023)

    Fulltext@MSK | Save